Nama Insights

CeriBell (CBLL)

Healthcare · Medical Devices · NASDAQ

CeriBell (CBLL) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.03B and a free-cash-flow yield of -4.3%. Over the most recent reported fiscal year, revenue grew 36.1%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the leading band of its market.
AI scorecard
Sell · 4.1/10
Negative, at the mild end of Sell. As of Nov 6, 2026.
Momentum
Leading · +103.1% over 12 months ex. last
Top 20% of its market on the past year's steady rise.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-18.8%
How far the last close sits under the highest price of the past five years.
Market cap$1.03B
Trailing P/E—
Price / book7.9
Price / sales10.0
FCF yield-4.3%
Dividend yield—
Gross margin88.9%
Operating margin-68.6%
Net margin-64.7%
Revenue growth (YoY)+36.1%
Revenue growth (3-yr annual)+50.9%
EPS growth (YoY)—
FCF/share growth (YoY)—
Beta0.9
ExchangeNASDAQ
SectorHealthcare
IndustryMedical Devices

CBLL earnings

Next report: Feb 23, 2027 (Q4 2026, EPS estimate -$0.49). Beat the EPS estimate in 4 of 4 recent quarters.

QuarterReportedEPSEstimateSurpriseRevenue
Q3 2026 Nov 3, 2026 -$0.49 -$0.52 +5.8% $29.34M
Q2 2026 Aug 10, 2026 -$0.40 -$0.46 +13.0% $28.10M
Q1 2026 May 11, 2026 -$0.38 -$0.39 +2.6% $26.49M
Q4 2025 Feb 24, 2026 -$0.36 -$0.41 +12.2% $24.78M

CBLL analyst price target

Median target $31.00 from 6 analysts, ranging $29.00 – $33.00.

Medical Devices peers

TickerCompanyMarket capP/E
ABT Abbott Laboratories $190.39B 20.4
MDT Medtronic $130.22B 17.8
SYK Stryker $124.06B 22.8
BSX Boston Scientific $61.96B 13.4
EW Edwards Lifesciences $58.73B 34.7
GEHC GE HealthCare Technologies $37.25B 16.8
PHG Koninklijke Philips $29.67B 15.2
DXCM DexCom $29.62B 29.7
Explore live CBLL data on Nama Insights →

CBLL FAQ

Is CBLL a buy?
Nama's AI scorecard currently rates CeriBell Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does CBLL report earnings?
CeriBell's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$0.49.
What is the CBLL price target?
The median analyst price target from 6 analysts is $31.00, with a range of $29.00 – $33.00.
Is CBLL Shariah compliant?
Nama's AAOIFI-style screen reads CeriBell as Can't Tell. A figure the screen needs is missing, so it can't tell.